Rush Eye Associates Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2012
NCT01708538
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Rush Eye Associates

Active Ingredients

Drugs in Phase 3 Trials (3)

aflibercept (zaltrap) (1 trial)

avibactam (Avycaz) (1 trial)

ceftaroline fosamil (teflaro) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetic Retinopathy (Phase 3)

Dilatation, Pathologic (Phase 3)

Edema (Phase 3)

Keratoconus (Phase 3)

Macular Edema (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 3